Apimeds Pharmaceuticals US (APUS) EBIT (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) reported EBIT of -$7.0 million for Q4 2025, down 2454.32% on a YoY basis from $299026.3 in Q4 2024, and down 281.73% quarter-over-quarter from -$1.8 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) EBIT (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported EBIT for 2 years, with the latest figure at -$7.0 million in Q4 2025.
- For the quarter ending Q4 2025, EBIT fell 2454.32% year-over-year to -$7.0 million; the trailing twelve-month figure through Dec 2025 stood at -$11.9 million (down 834.25% YoY), and the FY2025 full-year result was -$11.9 million, down 834.25% from the prior year.
- EBIT for Q4 2025 stood at -$7.0 million, down from -$1.8 million in the prior quarter.
- The five-year high for EBIT was -$271726.0 in Q1 2024, with the low at -$7.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 652.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 833.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 325.80 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 14.03 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 193.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 307.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -48.28 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -78.32 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 81.33 Mn |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - | -7.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.04 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -2.66 Mn |
| Mar 31, 2025 | -364,368.00 |
| Dec 31, 2024 | -275,613.00 |
| Sep 30, 2024 | -299,999.00 |
| Jun 30, 2024 | -427,757.00 |
| Mar 31, 2024 | -271,726.00 |